Drug resistance is the major cause of the failure of cancer chemotherapy, so one of the most important features in developing effective cancer therapeutic strategies is to overcome drug resistance. Quinoline moiety has become one of the most privileged structural motifs in anticancer agent discovery since its derivatives possess potent activity against various cancers including drug-resistant cancers. Several quinoline-based compounds which are represented by Anlotinib, Bosutinib, Lenvatinib, and Neratinib have already been applied in clinical practice to fight against cancers, so quinoline-based compounds are potential anticancer agents. The present short review article provides an overview of the recent advances of quinoline-based compounds with potential activity against drug-resistant cancers. The structure-activity relationship and mechanisms of action are also discussed.

耐药性是癌症化学疗法失败的主要原因，因此制定有效的癌症治疗策略的最重要特征之一就是克服耐药性。喹啉部分已成为抗癌剂发现中最优先的结构基序之一，因为它的衍生物对包括抗药性癌症在内的各种癌症均具有有效的活性。由Anlotinib，Bosutinib，Lenvatinib和Neratinib代表的几种基于喹啉的化合物已在临床实践中用于对抗癌症，因此基于喹啉的化合物是潜在的抗癌剂。本篇简短的综述文章概述了具有潜在抗药性的喹啉类化合物的最新研究进展。